← Leaderboards
Meghan E. Sise
Massachusetts General Hospital
$4,828,791
Attributed
$5,566,701
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,566,701 · 4
By mechanism
R01$4,450,201 · 2
K23$864,500 · 1
R03$252,000 · 1
Top collaborators
- Dennis G. Moledina2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Joseph Vincent Bonventre$46,605,730
- Andrew D Luster$52,151,359
- Donghai Wen$755,340
- Heidi Yeh$2,250,763
- Shiv Subramaniam Pillai$21,368,359
Others in their field
Other Emerging Leaders on “Renal Function”
- Robyn Lorraine Woods · Hennepin Healthcare Research Institute$19,109,927
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$14,031,836
- Jennifer Cohen Price · University Of California, San Francisco$9,197,178
- Vera Hoffman · Reveal Pharma$8,774,738
- Derek K Ng · Johns Hopkins University$8,295,783
- Petter Bjornstad · University Of Colorado Denver$5,735,275
Research focus
Renal FunctionBiological MarkersCohortEnrollmentKidneyPathway InteractionsGlomerular Filtration RateAffectKidney DiseasesChronic Kidney FailureRecruitProgramsProspectiveHealthcare SystemsFuturePositioning AttributeBiobankKidney BiopsyMassachusettsInfrastructureChronicAutomobile DrivingInjury To KidneyImmune
Grant awards (15)
Rapid Diagnosis and Treatment Response Phenotyping of Immune Checkpoint Inhibitor-Associated Acute Interstitial Nephritis$719,851
R01 · FY2025 · DK
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer$665,456
R01 · FY2025 · DK · contact PI
Rapid Diagnosis and Treatment Response Phenotyping of Immune Checkpoint Inhibitor-Associated Acute Interstitial Nephritis$755,970
R01 · FY2024 · DK
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer$682,247
R01 · FY2024 · DK · contact PI
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer$98,752
R01 · FY2024 · DK · contact PI
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer$726,628
R01 · FY2023 · DK · contact PI
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer$74,509
R01 · FY2023 · DK · contact PI
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer$726,788
R01 · FY2022 · DK · contact PI
Effect of Hepatitis C Virus Eradication on Chronic Kidney Disease Progression$172,600
K23 · FY2022 · DK · contact PI
Effect of Covid-19 on chronic kidney disease progression$126,000
R03 · FY2022 · DK · contact PI
Effect of Hepatitis C Virus Eradication on Chronic Kidney Disease Progression$172,600
K23 · FY2021 · DK · contact PI
Effect of Covid-19 on chronic kidney disease progression$126,000
R03 · FY2021 · DK · contact PI
Effect of Hepatitis C Virus Eradication on Chronic Kidney Disease Progression$172,600
K23 · FY2020 · DK · contact PI
Effect of Hepatitis C Virus Eradication on Chronic Kidney Disease Progression$172,600
K23 · FY2019 · DK · contact PI
Effect of Hepatitis C Virus Eradication on Chronic Kidney Disease Progression$174,100
K23 · FY2018 · DK · contact PI